Article
Debrisoquin oxidation genotype and susceptibility to lung cancer.
Clinical pharmacology and therapeutics - 1 Jan 1994
Agúndez J A, Martínez C, Ladero J M, Ledesma M C, Ramos J M, Martín R, Rodriguez A, Jara C, Benítez J
Abstract excerpt
The association between the polymorphism of the cytochrome P450 debrisoquin hydroxylase (CYP2D6) and lung cancer is controversial. Previous reports suggested a link between CYP2D6 phenotype and lung cancer, with poor metabolizers having reduced susceptibility. Nevertheless, negative findings have also been published. By using allele-specific amplification, we have studied the frequency of four CYP2D6 (wild type...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.